| Literature DB >> 25956387 |
Jose J Arenas Villafranca1,2, Cristobal López-Rodríguez3, Jimena Abilés4, Robin Rivera5, Norberto Gándara Adán6, Pilar Utrilla Navarro7.
Abstract
INTRODUCTION: An issue of recent research interest is excessive stoma output and its relation to electrolyte abnormalities. Some studies have identified this as a precursor of dehydration and renal dysfunction. A prospective study was performed of the complications associated with high-output stomas, to identify their causes, consequences and management.Entities:
Mesh:
Year: 2015 PMID: 25956387 PMCID: PMC4461994 DOI: 10.1186/s12937-015-0034-z
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Treatment protocol for high output stomas
| Detection and treatment of the underlying cause | |
|---|---|
| Before initiating pharmacological and nutritional treatment, the underlying cause of the HOS must be detected and treated: | |
| • Gastrointestinal infections ( | |
| • Related to the medication: | |
| • Prokinetic indicated drugs: metoclopramide, laxatives, erythromycin, etc. | |
| • Abrupt withdrawal of corticosteroids | |
| • Metformin also provokes increased stoma output | |
| • Bowel obstructions | |
| • Intra-abdominal sepsis | |
| • Inflammatory bowel disease | |
| • Short bowel syndrome | |
|
| ▪ Restrict fluid intake to 500–1000 ml/day. Isotonic drinks are the best option. |
| ▪ Perform intravenous hydration. | |
| ▪ Prescribe loperamide 2 mg before breakfast-lunch-dinner and at night. | |
| ▪ Monitoring: strict fluid balance, check body weight daily, perform complete blood analysis including electrolytes (magnesium, calcium, phosphorus, potassium and sodium). | |
| • Start oral or I/V supplementation of electrolytes if necessary, according to analysis results. | |
| ▪ Start nutritional assessment and treatment | |
| ▪ | |
| ▪ | |
|
| ▪ Continue the fluid intake restriction and the nutritional monitoring. Start SueroOral intake (2.5 g NaCl, 1.5 g KCl, 2.5 g HCO3Na, 1.5 g sugar and 1 L water) |
| ▪ Increase loperamide dose to 4 mg before breakfast-lunch-dinner and at night (maximum 16 mg/day). | |
| ▪ Start treatment with omeprazole 20 mg/day. If already prescribed, increase to 40 mg/day. | |
| ▪ If fat malabsorption, steatorrhoea, or pruritic bilious output is present, add | |
| ▪ Continue monitoring and electrolyte supplementation if necessary, as in | |
| ▪ | |
|
| ▪ Supplement with hydro- and lipid-soluble oral vitamins. |
| ▪ Maintain loperamide and add | |
| ▪ If fat malabsorption persists, increase cholestyramine dose to 4 g before breakfast-lunch-dinner. | |
| ▪ If HOS > 2000 ml | |
| ▪ Monitor fluid intake. | |
|
| |
| ▪ Avoid fluid intake during meals. | |
| ▪ It may be advisable to temporarily increase the salt content of foods in order to promote fluid reabsorption. | |
| ▪ Little is known about the use of soluble fibre. Insoluble fibre is contraindicated because of the risk of bowel obstruction. | |
| ▪ The effect of antidiarrhoeal microorganisms on HOS is unknown. | |
General characteristics of the population
| Baseline characteristics | Total patients (n = 43) |
|---|---|
| Sex (female/male) | 39.5/60.5 % |
| Age (median, years) | 66 (IR 58–73) |
| Cause of resection | |
| • | 74.4 % |
| • | 14.0 % |
| • | 11.6 % |
| BMI pre-surgery | 23.9 (IR 21.0–28.5) |
| Variation in BMI at discharge | −0.8 [IR (−2.6)−0.0] |
| Comorbidities: | |
| • | 16.3 % |
| • | 23.3 % |
| • | 4.8 % |
| • | 4.7 % |
| • | 39.5 % |
| Intervention (Urgent/elective) | 48.8/51.2 % |
| Type of stoma (Ileostomy/Colostomy) | 46.5/53.5 % |
| Diagnosis of malnutrition | 32.6 % |
| • | |
|
| 4.7 % |
| • | |
|
| 2.3 % |
|
| 18.6 % |
|
| 7.0 % |
| Neoadjuvant chemoradiation | |
| • | 13 % |
| • | 6 % |
| • | 12 % |
| • | 69 % |
| Post-surgery hospital stay (median, days) | 13 (IR 9–17) |
BMI: Body Mass Index, COPD: Chronic Obstructive Pulmonary Disease, IR: Interquartile range
Characteristics of the population with HOS (Early and Late) and the comparison with no HOS population
| Baseline characteristics | Patients without early HOS (n = 36) | Patients with early HOS (n = 7) |
| Patients without early or late HOS (n = 31) | Patients with late HOS (n = 6) |
|
|---|---|---|---|---|---|---|
| Sex (female/male) | 44.4/55.6 % | 14.3/85.7 % |
| 45/56 % | 33.3/66.7 % |
|
| Age (median, years) | 66 (IR 58–74) | 64 (IR 57–68) |
| 66 (IR 59–74) | 70 (IR 29–75) |
|
| Cause of resection | ||||||
| • | 71 % | 86 % |
| 71 % | 83 % |
|
| • | 17 % | 0 % | 16 % | 17 % | ||
| • | 12 % | 14 % | 13 % | 0 % | ||
| BMI pre-surgery or readmission | 23.9 (IR 21.1–27.2) | 24.4 (IR 20.7–33.1) |
| 23.9 (IR 20.4–28.5) | 23.1 (IR 19.7–29.4) |
|
| Variation in BMI at discharge | −0.6 [IR (−2.4)−(0.0)] | −1.5 [IR (−3.4)−(−0.4)] |
| - | - |
|
| Length of resection (median, cm) | 24.7 (IR 18.9–46.8) | 24.5 (IR 19.5–40.0) |
| 24.7 (IR 19.5–46.8) | 19.5 (IR 16.4–85.0) |
|
| Intervention (Urgent/Elective) | 50/50 % | 43/57 % |
| 48/52 % | 50/50 % |
|
| Type of stoma (Ileostomy/Colostomy) | 36/64 % | 100/0 % |
| 29/71 % | 83/17 % |
|
| Infection post-surgery | 31 % | 57 % |
| - | - |
|
| Presence of ileocaecal valve | 72 % | 71 % |
| 71 % | 83 % |
|
IBD: Inflammatory bowel disease, BMI: Body Mass Index, IR: Interquartile range